Cogan’s syndrome: new therapeutic approaches in the biological era

References

• Gluth MB, Baratz KH, Matteson EL, et al. Cogan syndrome: a retrospective review of 60 patients throughout a half century. Mayo Clin Proc. 2006;81:483–488.
   PubMed Web of Science ®Google Scholar
• Girasoli L, Cazzador D, Padoan R, et al. Update on vertigo in autoimmune disorders, from diagnosis to treatment. J Immunol Res. 2018;2018:5072582.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Kaiser-Kupfer MI, Mason P, et al. Cogan syndrome: studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine (Baltimore). 1980;59:426–441.
   PubMed Web of Science ®Google Scholar
• Grasland A, Pouchot J, Hachulla E, et al. Typical and atypical Cogan’s syndrome: 32 cases and review of the literature. Rheumatology (Oxford). 2004;43:1007–1015.
   PubMed Web of Science ®Google Scholar
• Vollertsen RS, McDonald TJ, Younge BR, et al. Cogan’s syndrome: 18 cases and a review of the literature. Mayo Clin Proc. 1986;61:344–361.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bluming AZ, Alroy J. Cogan’s syndrome: a systemic vasculitis. Am J Med. 1976;60:549–555.
   PubMed Web of Science ®Google Scholar
• Shamriz O, Tal Y, Gross M. Autoimmune inner ear disease: immune biomarkers, audiovestibular aspects, and therapeutic modalities of Cogan’s syndrome. J Immunol Res. 2018;2018:1–8.
   Web of Science ®Google Scholar
• Lunardi C, Bason C, Leandri M, et al. Autoantibodies to inner ear and endothelial antigens in Cogan’s syndrome. Lancet. 2002;360:915–921.
   PubMed Web of Science ®Google Scholar
• Berti E, Vannucci G, Lunardi C, et al. Identification of autoantibodies against inner ear antigens in a cohort of children with idiopathic sensorineural hearing loss. Autoimmunity. 2013;46:525–530.
   PubMed Web of Science ®Google Scholar
• Best C, Thömke F, Hitzler W, et al. Plasmapheresis as effective treatment in chronic active Cogan-I-syndrome. Immunol Lett. 2013;150:87–88.
   PubMed Web of Science ®Google Scholar
• Dekker JJ, Dinant HJ, Van Soesbergen RM. Cogan’s syndrome as an extra-articular manifestation of rheumatoid arthritis. Clin Rheumatol. 1996;15:374–377.
   PubMed Web of Science ®Google Scholar
• Ben Taarit C, Turki S, Chaabouni L, et al. Association of Cogan’s syndrome and rheumatoid arthritis. Rev Med Interne. 1996;17:860–861.
   PubMed Web of Science ®Google Scholar
• Edrees A, Tran J, Thompson G, et al. Cogan’s syndrome presenting as Sjögren’s syndrome followed by acute aortic regurgitation. Clin Rheumatol. 2003;22:156.
   PubMed Web of Science ®Google Scholar
• Tirelli G, Tomietto P, Quatela E, et al. Sudden hearing loss and Crohn disease: when Cogan syndrome must be suspected. Am J Otolaryngol. 2015;36:590–597.
   PubMed Web of Science ®Google Scholar
• Jung DH, Nadol JB, Folkerth RD, et al. Histopathology of the inner ear in a case with recent onset of Cogan’s syndrome: evidence for vasculitis. Ann Otol Rhinol Laryngol. 2016;125:20–24.
   PubMed Web of Science ®Google Scholar
• Van Doornum S, McColl G, Walter M, et al. Prolonged prodrome, systemic vasculitis, and deafness in Cogan’s syndrome. Ann Rheum Dis. 2001;60:69–71.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Pikus A, Kaiser-Kupfer M, et al. Successful treatment of sudden hearing loss in Cogan’s syndrome with corticosteroids. Arthritis Rheum. 1981;24:501–503.
   PubMedGoogle Scholar
• Bovo R, Ciorba A, Trevisi P, et al. Cochlear implant in Cogan syndrome. Acta Otolaryngol. 2011;131:494–497.
   PubMed Web of Science ®Google Scholar
• Bacciu A, Pasanisi E, Di Lella F, et al. Cochlear implantation in patients with Cogan syndrome: long-term results. Eur Arch Otorhinolaryngol. 2015;272:3201–3207.
   PubMed Web of Science ®Google Scholar
• Vollertsen RS. Vasculitis and Cogan’s syndrome. Rheum Dis Clin North Am. 1990;16:433–439.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Baykal HE, Rohrbach JM, et al. Cogan I syndrome: too often detected too late? A contribution to early diagnosis of Cogan I syndrome. Klin Monbl Augenheilkd. 1995;207:3–10.
   PubMed Web of Science ®Google Scholar
• Migliori G, Battisti E, Pari M, et al. A shifty diagnosis: cogan’s syndrome. A case report and review of the literature. Acta Otorhinolaryngol Ital. 2009;29:108–113.
   PubMed Web of Science ®Google Scholar
• Beccastrini E, Emmi G, Squatrito D, et al. Infliximab and Cogan’s syndrome. Clin Otolaryngol. 2010;35:441–442.
   PubMed Web of Science ®Google Scholar
• Durtette C, Hachulla E, Resche-Rigon M, et al. Cogan syndrome: characteristics, outcome and treatment in a French nationwide retrospective study and literature review. Autoimmun Rev. 2017;16:1219–1223.
   PubMed Web of Science ®Google Scholar
• Bunker DR, Kerr LD. Rituximab not effective for hearing loss in Cogan’s syndrome. Case Rep Rheumatol. 2016;2016:8352893.
   PubMedGoogle Scholar
• Guasamucaro-Castillo MG, Bonito-Torrealba FA, Maldonado T, et al. Cogan syndrome and spondyloarthritis: case report. Reumatol Clin. 2017. doi: 10.1016/j.reuma.2017.11.005.
   PubMed Web of Science ®Google Scholar
• Shibuya M, Fujio K, Morita K, et al. Successful treatment with tocilizumab in a case of Cogan’s syndrome complicated with aortitis. Mod Rheumatol. 2013;23:577–581.
   PubMed Web of Science ®Google Scholar
• Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly. 2002;132:414–422.
   PubMed Web of Science ®Google Scholar
• Fricker M, Baumann A, Wermelinger F, et al. A novel therapeutic option in Cogan diseases? TNF-α blockers. Rheumatol Int. 2007;27:493–495.
   PubMed Web of Science ®Google Scholar
• Ghadban R, Couret M, Zenone T. Efficacy of Infliximab in Cogan’s syndrome. J Rheumatol. 2008;35:2453.
   PubMed Web of Science ®Google Scholar
• Orsoni JG, Laganà B, Rubino P, et al. Rituximab ameliorated severe hearing loss in Cogan’s syndrome: a case report. Orphanet J Rare Dis. 2010;5:18.
   PubMed Web of Science ®Google Scholar
• Tayer-Shifman OE, Ilan O, Tovi H, et al. Cogan’s syndrome–clinical guidelines and novel therapeutic approaches. Clin Rev Allergy Immunol. 2014;47:65–72.
   PubMed Web of Science ®Google Scholar
• Touma Z, Nawwar R, Hadi U, et al. The use of TNF-α blockers in Cogan’s syndrome. Rheumatol Int. 2007;27:995–996.
   PubMed Web of Science ®Google Scholar
• Matteson EL, Choi HK, Poe DS, et al. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study. Arthritis Rheum. 2005;53:337–342.
   PubMed Web of Science ®Google Scholar
• Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501.
   PubMed Web of Science ®Google Scholar
• Segal B, Rhodus NL, Patel K. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:778–787.
   PubMed Web of Science ®Google Scholar
• Van Den Bosch F, Kruithof E, De Vos M, et al. Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet. 2000;356:1821–1822.
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !? Ann Rheum Dis. 2000;59:404–407.
   PubMed Web of Science ®Google Scholar
• Morovic Vergles J, Radic M, Kovacic J, et al. Successful use of adalimumab for treating rheumatoid arthritis with autoimmune sensorineural hearing loss: two birds with one stone. J Rheumatol. 2010;37:1080–1081.
   PubMed Web of Science ®Google Scholar
• Jachiet M, Lependu C, Fragny D, et al. Severe deafness associated with Crohn’s disease and spondylarthropathy: successful treatment with anti-TNF. Rheumatology (Oxford). 2013;52:1145–1147.
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383–3389.
   PubMed Web of Science ®Google Scholar
• Cohen S, Roland P, Shoup A, et al. A pilot study of rituximab in immune-mediated inner ear disease. Audiol Neurootol. 2011;16:214–221.
   PubMed Web of Science ®Google Scholar
• Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11–20.
   PubMed Web of Science ®Google Scholar
• D‘Aguanno V, Ralli M, de Vincentiis M, et al. Optimal management of Cogan‘s syndrome: a multidisciplinary approach. J Multidiscip Healthc. 2017;11:1–11.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Tomemori T, Suzuki S, et al. Low-dose oral methotrexate for the management of childhood Cogan’s syndrome: a case report. Clin Rheumatol. 2007;26:2201–2203.
   PubMed Web of Science ®Google Scholar
• Richardson B. Methotrexate therapy for hearing loss in Cogan’s syndrome. Arthritis Rheum. 1994;37:1559–1561.
   PubMedGoogle Scholar
• Pouchot J, Vinceneux P, Bouccara D, et al. Methotrexate as a steroid-sparing agent in Cogan’s syndrome: comment on the concise communication by Richardson. Arthritis Rheum. 1995;38:1348–1349.
   PubMedGoogle Scholar
• Riente L, Taglione E, Berrettini S. Efficacy of methotrexate in Cogan’s syndrome. J Rheumatol. 1996;23:1830–1831.
   PubMed Web of Science ®Google Scholar
• Harris JP, Weisman MH, Derebery JM, et al. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate. JAMA. 2003;290:1875.
   PubMed Web of Science ®Google Scholar
• Allen NB, Cox CC, Cobo M, et al. Use of immunosuppressive agents in the treatment of severe ocular and vascular manifestations of Cogan’s syndrome. Am J Med. 1990;88:296–301.
   PubMed Web of Science ®Google Scholar
• Vaiopoulos G, Sfikakis PP, Skoumas B, et al. Lack of response to corticosteroids and pulse cyclophosphamide therapy in Cogan’s syndrome. Clin Rheumatol. 1994;13:110–112.
   PubMed Web of Science ®Google Scholar
• Lydon EJ, Barisoni L, Belmont HM. Cogan’s syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission. Clin Exp Rheumatol. 2009;27:S144.
   PubMed Web of Science ®Google Scholar
• Hirvonen TP, Aalto H. Recovery of bilateral vestibular loss in Cogan’s syndrome–a case report. Otol Neurotol. 2013;34:1736–1738.
   PubMed Web of Science ®Google Scholar
• Di Leo E, Dambra PP, Capuzzimati L, et al. A case of Cogan’s syndrome resolved with mycophenolate sodium. Eur J Clin Invest. 2008;38:605.
   PubMed Web of Science ®Google Scholar
• Orsoni JG, Zavota L, Vincenti V, et al. Cogan syndrome in children: early diagnosis and treatment is critical to prognosis. Am J Ophthalmol. 2004;137:757–758.
   PubMed Web of Science ®Google Scholar
• Mora P, Calzetti G, Ghirardini S, et al. Cogan’s syndrome: state of the art of systemic immunosuppressive treatment in adult and pediatric patients. Autoimmun Rev. 2017;16:385–390.
   PubMed Web of Science ®Google Scholar
• Stone JH. Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med. 2005;352:351–361.
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67:625–630.
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002;301:418–426.
   PubMed Web of Science ®Google Scholar
• Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548–1561.
   PubMed Web of Science ®Google Scholar
• Rahman MU, Poe DS, Choi HK. Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol. 2001;22:619–624.
   PubMed Web of Science ®Google Scholar
• Cohen S, Shoup A, Weisman MH, et al. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol. 2005;26:903–907.
   PubMed Web of Science ®Google Scholar